Incidence of proximal renal tubular dysfunction in patients on tenofovir disoproxil fumarate

International Journal of STD and AIDS

Volumn 21, Issue 2, 2010, Pages 150-151

  Quinn, K J ^a   Emerson, C R ^a   Dinsmore, W W ^a   Donnelly, C M ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; PHOSPHATE; TENOFOVIR DISOPROXIL;

DRUG SAFETY; DRUG TOLERABILITY; FANCONI RENOTUBULAR SYNDROME; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; INCIDENCE; KIDNEY FUNCTION; LETTER; PATIENT MONITORING; PHOSPHATE BLOOD LEVEL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUBULAR DYSFUNCTION;

ADENINE; ANTI-HIV AGENTS; FANCONI SYNDROME; GREAT BRITAIN; HIV INFECTIONS; HUMANS; INCIDENCE; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES;

EID: 75449104004     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2009.009464     Document Type: Letter

References (6)

1. De Silva TI, Post FA, Griffin MD, Dockell DH. HIV-1 infection and the kidney: an evolving challenge in HIV medicine. Mayo Clin Proc 2007;82:1103-16
2. Fux CA, Simcock M, Furner H, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 2007;12:1165-73
3. Gupta SK, Eustace JA, Szczech LA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infec Dis 2005;40:1559-85
4. Woodward CLN, Johnson MA, Connolly JO, et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009;10:482-87
5. Moore DJ, Rosh AJ. Hypophosphatemia: treatment & medication [Online]. 2009?;[4 screens]. See http://emedicine.medscape.com/article/767955-overview (last checked 22 September 2009)
6. Day SL, Leake Date HA, Bannister A, Hankins M, Fisher M. Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. JAIDS 2005;38:301-4